The reporting of pulmonary nodule results by letter in a lung cancer screening setting.


Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
06 2022
Historique:
received: 03 02 2022
revised: 04 04 2022
accepted: 14 04 2022
pubmed: 30 4 2022
medline: 7 6 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

Pulmonary nodules are commonly found in Lung Cancer Screening (LCS), with results typically communicated by face-to-face or telephone consultation. Providing LCS on a population basis requires resource efficient and scalabe communication methods. Written communication provides one such method. Here, we assess participant satisfaction with this approach in a LCS setting and investigate characteristics associated with dissatisfaction. The SUMMIT Study is a prospective observational cohort study which aims to assess the implementation of Low-Dose Computed Tomography (LDCT) scanning for LCS in a high-risk population and validate a multi-cancer early detection blood test (NCT03934866). Participants with indeterminate pulmonary nodules requiring a three-month interval LDCT were informed of their result by postal letter and given a face-to-face appointment with a study practitioner at their interval LDCT appointment. At this appointment, having previously received their results letter, participants were verbally asked questions to assess their satisfaction with, and preferences for, methods of results communication. 1,900 participants were included in the analysis. 82.8% (n = 1573) were satisfied with receiving their results by letter, with 2.9% (n = 55) reporting dissatisfaction. 86.3% (n = 1640) stated it was their preferred communication method and 77.3% (n = 1469) reported that their letter contained the right amount of information. Participants from less deprived socioeconomic quintiles were more likely to report that the letter contained insufficient information and individuals aged ≥ 70 years were less likely to do so. Although 13.7% (n = 261) participants had discussed their results with their General Practitioner (GP) prior to the study visit, 83.9% (n = 219) of these participants were satisfied with receiving results by letter, with the same proportion preferring this communication method. We report high participant satisfaction with the reporting of pulmonary nodule results by letter in a LCS setting. We believe this provides a feasible route forward for large-scale screening programmes.

Identifiants

pubmed: 35487105
pii: S0169-5002(22)00411-1
doi: 10.1016/j.lungcan.2022.04.009
pmc: PMC10442288
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03934866']

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

46-49

Subventions

Organisme : Wellcome Trust
ID : WT107963AIA
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/W025051/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : EDDCPGM\100002
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C50664/A24460
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Chest. 2018 Apr;153(4):1004-1015
pubmed: 29066390
Thorax. 2016 Feb;71(2):161-70
pubmed: 26645413
Transl Lung Cancer Res. 2021 May;10(5):2427-2440
pubmed: 34164290
Chest. 2020 Sep;158(3):1240-1249
pubmed: 32387521
Lung Cancer. 2020 Oct;148:12-19
pubmed: 32771715
Thorax. 2020 Oct;75(10):831-832
pubmed: 32792406
Thorax. 2019 Apr;74(4):405-409
pubmed: 29440588

Auteurs

Jennifer L Dickson (JL)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

Amyn Bhamani (A)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

Samantha L Quaife (SL)

Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Carolyn Horst (C)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

Sophie Tisi (S)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

Helen Hall (H)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

Priyam Verghese (P)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

Andrew Creamer (A)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

Ruth Prendecki (R)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

John McCabe (J)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.

Kylie Gyertson (K)

University College London Hospitals NHS Foundation Trust, London, UK.

Vicky Bowyer (V)

University College London Hospitals NHS Foundation Trust, London, UK.

Ethaar El-Emir (E)

University College London Hospitals NHS Foundation Trust, London, UK.

Alice Cotton (A)

University College London Hospitals NHS Foundation Trust, London, UK.

Simranjit Mehta (S)

University College London Hospitals NHS Foundation Trust, London, UK.

Fanta Bojang (F)

University College London Hospitals NHS Foundation Trust, London, UK.

Claire Levermore (C)

University College London Hospitals NHS Foundation Trust, London, UK.

Anne-Marie Mullin (AM)

Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.

Jonathan Teague (J)

Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.

Laura Farrelly (L)

Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.

Arjun Nair (A)

University College London Hospitals NHS Foundation Trust, London, UK.

Anand Devaraj (A)

Royal Brompton and Harefield NHS Trust, London, UK; National Heart and Lung Institute, Imperial College London, London, UK.

Allan Hackshaw (A)

Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.

Sam M Janes (SM)

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK. Electronic address: s.janes@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH